Identification

Name
Dienestrol
Accession Number
DB00890  (APRD00917)
Type
Small Molecule
Groups
Approved, Investigational
Description

Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. Conditions that are treated with vaginal estrogens include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and inflammation of the urethra (atrophic urethritis).

Structure
Thumb
Synonyms
  • alpha-dienestrol diacetate
  • Cycladiene
  • Dehydrostilbestrol
  • Dienestrol
  • Diènestrol
  • Dienestrolum
  • DV
Product Ingredients
IngredientUNIICASInChI Key
Dienestrol diacetateD20D148WPQ24705-61-1YWLLGDVBTLPARJ-OXAZHYLESA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ortho Dienestrol CrmCream.01 %VaginalOrtho Pharmaceutical, Division Of Janssen Ortho Inc.1951-12-312002-08-02Canada
International/Other Brands
Estraguard / Estraguard / Estroral / Ortho Dienestrol (Ortho-McNeil Pharmaceutical) / Restrol / Retalon / Sexadien (LEO Pharma A/S) / Synestrol
Categories
UNII
RRW32X4U1F
CAS number
13029-44-2
Weight
Average: 266.3343
Monoisotopic: 266.13067982
Chemical Formula
C18H18O2
InChI Key
NFDFQCUYFHCNBW-SCGPFSFSSA-N
InChI
InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+
IUPAC Name
4-[4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
SMILES
CC=C(C(=CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1

Pharmacology

Indication

For use in the treatment of atrophic vaginitis and kraurosis vulvae.

Pharmacodynamics

Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Mechanism of action

Dienestrol is a synthetic, non-steroidal estrogen. Estrogens passively diffuse into target cells of responsive tissues, complex with the estrogen receptors, and enter the cell's nucleus to initiate or enhance gene transcription of protein synthesis after binding to DNA.

TargetActionsOrganism
AEstrogen receptor alpha
agonist
Human
USex hormone-binding globulinNot AvailableHuman
Absorption

Systemic absorption and mode of action of dienestrol are undetermined.Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Volume of distribution
Not Available
Protein binding

50 to 80%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Dienestrol.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Dienestrol.Experimental, Illicit
AbciximabDienestrol may decrease the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the thrombogenic activities of Dienestrol.Approved, Investigational
AcenocoumarolDienestrol may decrease the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenAcetaminophen may increase the thrombogenic activities of Dienestrol.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Dienestrol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dienestrol.Experimental, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Dienestrol.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Dienestrol.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Dienestrol.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the thrombogenic activities of Dienestrol.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Dienestrol.Approved, Investigational
AncrodDienestrol may decrease the anticoagulant activities of Ancrod.Approved, Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Dienestrol.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Dienestrol.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Dienestrol.Investigational
Anthrax immune globulin humanDienestrol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
AntipyrineAntipyrine may increase the thrombogenic activities of Dienestrol.Approved, Investigational
Antithrombin III humanDienestrol may decrease the anticoagulant activities of Antithrombin III human.Approved
AntrafenineAntrafenine may increase the thrombogenic activities of Dienestrol.Approved
ApixabanDienestrol may decrease the anticoagulant activities of Apixaban.Approved
ArdeparinDienestrol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanDienestrol may decrease the anticoagulant activities of Argatroban.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Dienestrol.Investigational
BalsalazideBalsalazide may increase the thrombogenic activities of Dienestrol.Approved, Investigational
BecaplerminDienestrol may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Dienestrol.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dienestrol.Approved, Vet Approved
BivalirudinDienestrol may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BromfenacBromfenac may increase the thrombogenic activities of Dienestrol.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dienestrol.Approved
BufexamacBufexamac may increase the thrombogenic activities of Dienestrol.Approved, Experimental
Capromab pendetideDienestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinCapsaicin may increase the thrombogenic activities of Dienestrol.Approved
CarprofenCarprofen may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved, Withdrawn
CelecoxibCelecoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
CertoparinDienestrol may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Dienestrol.Approved
ChlorphenesinChlorphenesin may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the thrombogenic activities of Dienestrol.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Dienestrol.Approved, Investigational
CimicoxibCimicoxib may increase the thrombogenic activities of Dienestrol.Investigational
CisplatinCisplatin may increase the thrombogenic activities of Dienestrol.Approved
Citric AcidDienestrol may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Dienestrol.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Dienestrol.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Dienestrol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Dienestrol.Approved
Clodronic AcidClodronic Acid may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Vet Approved
Conestat alfaDienestrol may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Dienestrol.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Dienestrol.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Dienestrol.Approved, Investigational
Dabigatran etexilateDienestrol may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDienestrol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidDienestrol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanDienestrol may decrease the anticoagulant activities of Darexaban.Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Dienestrol.Approved, Investigational
DesirudinDienestrol may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Dienestrol.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Dienestrol.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Dienestrol.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Dienestrol.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Dienestrol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Dienestrol.Vet Approved
DexibuprofenDexibuprofen may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DexketoprofenDexketoprofen may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DextranDienestrol may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
DicoumarolDienestrol may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Dienestrol.Approved
DiflunisalDiflunisal may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Dienestrol.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Dienestrol.Approved
DrospirenoneDrospirenone may increase the thrombogenic activities of Dienestrol.Approved
DroxicamDroxicam may increase the thrombogenic activities of Dienestrol.Withdrawn
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Dienestrol.Approved
Edetic AcidDienestrol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDienestrol may decrease the anticoagulant activities of Edoxaban.Approved
EnoxaparinDienestrol may decrease the anticoagulant activities of Enoxaparin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Dienestrol.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Dienestrol.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Dienestrol.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Dienestrol.Approved
EtanerceptEtanercept may increase the thrombogenic activities of Dienestrol.Approved, Investigational
Ethyl biscoumacetateDienestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Dienestrol.Approved, Investigational
FenoprofenFenoprofen may increase the thrombogenic activities of Dienestrol.Approved
Ferulic acidDienestrol may decrease the anticoagulant activities of Ferulic acid.Experimental
Fish oilFish oil may increase the thrombogenic activities of Dienestrol.Approved, Nutraceutical
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Dienestrol.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Dienestrol.Approved, Investigational
FluindioneDienestrol may decrease the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Dienestrol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Dienestrol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Dienestrol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Dienestrol.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Dienestrol.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Dienestrol.Approved, Investigational
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Dienestrol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Dienestrol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Dienestrol.Approved
FlurbiprofenFlurbiprofen may increase the thrombogenic activities of Dienestrol.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Dienestrol.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dienestrol.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Dienestrol.Approved
FondaparinuxDienestrol may decrease the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumDienestrol may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Dienestrol.Approved, Investigational, Withdrawn
GabexateDienestrol may decrease the anticoagulant activities of Gabexate.Investigational
GinsengGinseng may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Nutraceutical
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Dienestrol.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Dienestrol.Investigational
HeparinDienestrol may decrease the anticoagulant activities of Heparin.Approved, Investigational
Human C1-esterase inhibitorDienestrol may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dienestrol.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dienestrol.Approved, Vet Approved
IbuprofenIbuprofen may increase the thrombogenic activities of Dienestrol.Approved
IcosapentIcosapent may increase the thrombogenic activities of Dienestrol.Approved, Nutraceutical
IdraparinuxDienestrol may decrease the anticoagulant activities of Idraparinux.Investigational
IndomethacinIndomethacin may increase the thrombogenic activities of Dienestrol.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Dienestrol.Investigational
KetoprofenKetoprofen may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
KetorolacKetorolac may increase the thrombogenic activities of Dienestrol.Approved
LenalidomideDienestrol may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinDienestrol may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanDienestrol may decrease the anticoagulant activities of Letaxaban.Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Dienestrol.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Dienestrol.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Dienestrol.Approved
LornoxicamLornoxicam may increase the thrombogenic activities of Dienestrol.Approved, Investigational
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Dienestrol.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the thrombogenic activities of Dienestrol.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Dienestrol.Investigational
Meclofenamic acidMeclofenamic acid may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Dienestrol.Approved
Mefenamic acidMefenamic acid may increase the thrombogenic activities of Dienestrol.Approved
MelagatranDienestrol may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Dienestrol.Vet Approved
MeloxicamMeloxicam may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
MesalazineMesalazine may increase the thrombogenic activities of Dienestrol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol.Approved, Vet Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Dienestrol.Approved, Vet Approved
MorniflumateMorniflumate may increase the thrombogenic activities of Dienestrol.Approved
NabumetoneNabumetone may increase the thrombogenic activities of Dienestrol.Approved
NadroparinDienestrol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatDienestrol may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NaproxenNaproxen may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Dienestrol.Investigational
NepafenacNepafenac may increase the thrombogenic activities of Dienestrol.Approved, Investigational
Niflumic AcidNiflumic Acid may increase the thrombogenic activities of Dienestrol.Approved
NimesulideNimesulide may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Withdrawn
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Dienestrol.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Dienestrol is combined with Ospemifene.Approved, Investigational
OtamixabanDienestrol may decrease the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the thrombogenic activities of Dienestrol.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Dienestrol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Dienestrol.Approved
Pentaerythritol TetranitrateDienestrol may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateDienestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneDienestrol may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDienestrol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the thrombogenic activities of Dienestrol.Approved, Vet Approved
PiroxicamPiroxicam may increase the thrombogenic activities of Dienestrol.Approved, Investigational
PomalidomidePomalidomide may increase the thrombogenic activities of Dienestrol.Approved
Potassium CitrateDienestrol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Dienestrol.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Dienestrol.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Dienestrol.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dienestrol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dienestrol.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Dienestrol.Approved, Experimental, Investigational
Protein CDienestrol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanDienestrol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDienestrol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ResveratrolResveratrol may increase the thrombogenic activities of Dienestrol.Approved, Experimental, Investigational
ReviparinDienestrol may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Dienestrol.Approved
RivaroxabanDienestrol may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Dienestrol.Approved, Investigational
Salicylic acidSalicylic acid may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the thrombogenic activities of Dienestrol.Approved
SeliciclibSeliciclib may increase the thrombogenic activities of Dienestrol.Investigational
Sodium CitrateDienestrol may decrease the anticoagulant activities of Sodium Citrate.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Dienestrol.Approved, Investigational
SulfasalazineSulfasalazine may increase the thrombogenic activities of Dienestrol.Approved
SulindacSulindac may increase the thrombogenic activities of Dienestrol.Approved, Investigational
SulodexideDienestrol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the thrombogenic activities of Dienestrol.Approved, Withdrawn
TalniflumateTalniflumate may increase the thrombogenic activities of Dienestrol.Approved
TenoxicamTenoxicam may increase the thrombogenic activities of Dienestrol.Approved
ThalidomideDienestrol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Dienestrol.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Dienestrol.Approved
Tiaprofenic acidTiaprofenic acid may increase the thrombogenic activities of Dienestrol.Approved
TipranavirDienestrol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Dienestrol.Approved, Withdrawn
TolmetinTolmetin may increase the thrombogenic activities of Dienestrol.Approved
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Dienestrol.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the thrombogenic activities of Dienestrol.Approved
TroxerutinDienestrol may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Dienestrol.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Dienestrol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational, Withdrawn
Vitamin CThe serum concentration of Dienestrol can be increased when it is combined with Vitamin C.Approved, Nutraceutical
WarfarinDienestrol may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranDienestrol may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Short, W.F. and Hobday, G.1; U.S. Patent 2,464,203; March 15,1949; assigned to Boots Pure Drug Company Limited, England. Adler, E.; U.S. Patent 2,465,505; March 29,1949; assigned to Hoffmann-La Roche Inc.

General References
Not Available
External Links
KEGG Drug
D00898
KEGG Compound
C08090
PubChem Compound
667476
PubChem Substance
46504661
ChemSpider
580857
BindingDB
40491
ChEBI
4518
ChEMBL
CHEMBL1018
Therapeutic Targets Database
DAP001015
PharmGKB
PA164745534
RxList
RxList Drug Page
Wikipedia
Dienestrol
ATC Codes
G03CB01 — DienestrolG03CC02 — Dienestrol
MSDS
Download (75.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBipolar Disorder (BD) / Mania1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil pharmaceutical inc
  • Sanofi aventis us llc
  • Solvay pharmaceuticals
Packagers
  • Spectrum Pharmaceuticals
Dosage forms
FormRouteStrength
CreamVaginal.01 %
Prices
Unit descriptionCostUnit
Dienestrol powder442.23USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)233-234Short, W.F. and Hobday, G.1; U.S. Patent 2,464,203; March 15,1949; assigned to Boots Pure Drug Company Limited, England.
water solubility3 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.9Not Available
logS-4.95ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0123 mg/mLALOGPS
logP5.18ALOGPS
logP4.83ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.1ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity84.36 m3·mol-1ChemAxon
Polarizability30.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier-0.7087
Caco-2 permeable+0.8916
P-glycoprotein substrateNon-substrate0.5491
P-glycoprotein inhibitor INon-inhibitor0.7795
P-glycoprotein inhibitor IINon-inhibitor0.9557
Renal organic cation transporterNon-inhibitor0.8322
CYP450 2C9 substrateNon-substrate0.7849
CYP450 2D6 substrateNon-substrate0.8857
CYP450 3A4 substrateNon-substrate0.544
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8605
CYP450 2D6 inhibitorNon-inhibitor0.8201
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8844
Ames testNon AMES toxic0.9658
CarcinogenicityNon-carcinogens0.7133
BiodegradationNot ready biodegradable0.7876
Rat acute toxicity1.8229 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7994
hERG inhibition (predictor II)Non-inhibitor0.8584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.48 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Styrenes / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Stilbene / Styrene / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols, olefinic compound (CHEBI:4518)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Juriansz RL, Huseby RA, Wilcox RB: Interactions of putative estrogens with the intracellular receptor complex in mouse Leydig cells: relationship to preneoplastic hyperplasia. Cancer Res. 1988 Jan 1;48(1):14-8. [PubMed:3334987]
  2. Grove RI, Korach KS: Estrogen stimulation of phosphatidylinositol metabolism in mouse uterine tissue. Endocrinology. 1987 Sep;121(3):1083-8. [PubMed:3622377]
  3. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997 Mar;138(3):863-70. [PubMed:9048584]
  4. Chae K, Lindzey J, McLachlan JA, Korach KS: Estrogen-dependent gene regulation by an oxidative metabolite of diethylstilbestrol, diethylstilbestrol-4',4"-quinone. Steroids. 1998 Mar;63(3):149-57. [PubMed:9558716]
  5. Bovee TF, Helsdingen RJ, Rietjens IM, Keijer J, Hoogenboom RL: Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109. [PubMed:15276617]
  6. Maru BS, Tobias JH, Rivers C, Caunt CJ, Norman MR, McArdle CA: Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12. doi: 10.1016/j.bone.2008.09.016. Epub 2008 Oct 11. [PubMed:18976723]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:48